S42– KP Integrated Cardiovascular Disease (CVD) Risk Reduction Guidelines

2010 ◽  
Vol 143 (1_suppl) ◽  
pp. 32-33
Author(s):  
Craig Robbins ◽  
Wiley Chan
Author(s):  
Chamberlain Obialo ◽  
Elizabeth Ofili ◽  
Keith Norris

Cardiovascular disease (CVD) burden is several-fold higher in patients with chronic kidney disease (CKD). Although statins have been shown to provide significant CVD benefits in both the general population and patients with CKD, this has not translated into survival advantage in patients with advanced CKD or on dialysis. It has been reported that CVD risk continues to escalate as CKD progresses to end-stage kidney disease (ESKD); however, the CVD risk reduction by statins appears to decline as patients’ progress from the early to later stages of CKD. Statins have also been associated with a higher incidence of stroke in ESKD patients. Thus, the CVD benefits of statins in ESKD remain questionable.


2011 ◽  
Vol 10 (4) ◽  
pp. 4-9 ◽  
Author(s):  
R. G. Oganov ◽  
A. V. Kontsevaya ◽  
A. M. Kalinina

Aim. To analyze the social and economic burden of cardiovascular disease (CVD) in the Russian Federation for the period of 2006-2009. Material and methods. The analysis of the economic CVD burden included direct spending and economic loss related to CVD. Direct spending included hospitalization, ambulance service use, out-patient visits, high medical technologies, and out-patient pharmaceutical treatment. Economic loss included the loss in gross domestic product (GDP) due to death or disability in working-age people, as well as the disability benefits. Results. Total economic burden of CVD for 2008-2009 exceeded 1 trillion RUB, or 3 % of GDP for the respective period. Only one-fifth (21,3 %) of total economic burden of CVD in 2009 was represented by direct costs of the healthcare system. As much as 78,7 % of the total economic burden of CVD was represented by such indirect costs as economic loss, mostly due to premature mortality in working-age men. Conclusion. Substantial economic burden of CVD in theRussian Federation requires increased funding of preventive programs, aimed at CVD risk reduction, and healthcare optimization programs. This increased funding should facilitate mortality risk reduction in the working-age population.


Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Teruhiko Matsushima ◽  
Susumu Koseki ◽  
Haruo Nakamura

Background: The metabolic syndrome is related to an increased risk of cardiovascular disease (CVD), as reported by numerous studies. In this analysis, we investigated the relationship between the metabolic syndrome (MetSyn) and CVD risk in hypercholesterolemic patients and the effect of pravastatin treatment in the MEGA Study population. Methods: The MetSyn was defined according to modified National Cholesterol Education Program (NCEP) criteria, namely, the presence of three or more risk factors: 1)obesity (body mass index ≥25 kg/m 2 ), 2)hypertriglyceridemia (≥150 mg/dL), 3)low HDL cholesterol (<40 mg/dL in men and <50 mg/dL in women), 4)hypertension (SBP≥130 mmHg and/or DBP≥85 mmHg), 5)hyperglycemia (fasting glucose ≥100 mg/dL). The risk of CVD and total mortality was compared in patients with and without MetSyn. The effect of pravastatin plus diet therapy in the patients with MetSyn was compared to those without MetSyn, and moreover these comparisons were conducted in two groups, divided according to their LDL cholesterol levels (cut point: 156.9 mg/dL). Results: A total of 2,636 (33.7%) of the 7,832 hypercholesterolemic patients enrolled in MEGA had MetSyn. A 1.9 times higher incidence of CVD was found in the patients with, compared to those without, MetSyn. The risk of CVD in patients with MetSyn was very similar to that in patients with high LDL cholesterol (≥156.9 mg/dL) and with low LDL cholesterol (<156.9 mg/dL). Notably, a 36% significant risk reduction for CVD and 50% risk reduction for total mortality were observed in the patients with MetSyn treated with pravastatin plus diet treatment compared to diet therapy alone. Moreover, the greatest CVD risk reduction was observed in the high LDL-C group with MetSyn compared to those without MetSyn (Hazard ratio 0.44 vs. 0.56, respectively, interaction p=0.07). Conclusion: Metabolic syndrome increases the risk of CVD regardless of the presence or absence of hypercholesterolemia. Diet plus pravastatin treatment is effective for the prevention of CVD for patients with hypercholesterolemia and MetSyn.


2019 ◽  
Vol 31 (1) ◽  
pp. 76-86 ◽  
Author(s):  
Padmavathy Ramaswamy ◽  
Nitha Mathew Joseph ◽  
Jing Wang

Introduction: The risk for cardiovascular disease (CVD) is higher in South Asians (SAs) than in other ethnic groups. The purpose of this review is to explore SAs’ health beliefs regarding CVD risk and risk reduction behaviors including physical activity and healthy diet. Methodology: An integrative review was conducted to examine the peer-reviewed literature published before May 2017. Searches from PubMed, Scopus, and CINAHL yielded 1 mixed-method, 4 quantitative, and 14 qualitative studies. Results: Stress, lack of exercise, and high-fat diet were perceived as causes of CVD in most studies. Lack of time, sociocultural norms, and insufficient guidance from health care providers were perceived barriers to CVD risk reduction. Exercise and healthy diet were perceived to be beneficial in a few studies. Cues to action included information from community leaders and health care providers. Discussion: Understanding the unique health beliefs of SAs regarding CVD is important in planning and delivering culturally competent preventive and educational services.


2021 ◽  
Vol 20 (Supplement_1) ◽  
Author(s):  
J Miller ◽  
L Williams ◽  
A Alhurani ◽  
Z Saleh ◽  
A Bailey ◽  
...  

Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): NIH/National Institute of Nursing Research, 1RC2NR011948 Introduction Approximately 10% of the 2.2 million prisoners in the US have a diagnosis of cardiovascular disease (CVD) and in 2016, 28% of all deaths in custody were attributable to CVD. Black race, inadequate health literacy, and poor perceived control are predictors of increased cardiovascular disease (CVD) risk, which are prevalent in prisoners. However, little is known about the relationships among race, health literacy, and perceived control in CVD risk for male prisoners. Objective The purpose of this study was to explore the relationships among race, health literacy, perceived control, and CVD risk while controlling for well-known risk factors (education, partner status, and body mass index) in male prisoners. Methods We used baseline data from 349 male prisoners in a biobehavioral CVD risk reduction intervention. Health literacy was measured using the Newest Vital Sign and perceived control by the Control Attitudes Scale- Revised. CVD risk was quantified with the Framingham Risk Score (FRS). Three indirect effects of race on CVD risk were examined using serial mediation model with two sequential mediators (i.e., health literacy and perceived control) and 95% confidence intervals from 5000 bootstrap samples. Results Of the participants (mean age = 36 + 10 years), 64.2% were white and 35.8% were black. Mean education level was 12 years and most (85.8%) were not married or partnered. Mean BMI was 28.3 + 5.0. Mean FRS was 6.63 + 4.90, indicating risk percentages of 2.3 to 13.3% over the next ten years. Black prisoners were younger (35 + 9 versus 37 + 10, p = .047) and had lower levels of health literacy (3.84 + 1.90 versus 4.69 + 1.63, p &lt; .001) than white prisoners. No statistically significant differences in perceived control, education, partner status, or body mass index were noted between races. All three indirect effects of race on CVD were significant while the direct effect of race was not. Compared to white prisoners, black prisoners had higher levels of CVD risk through health literacy (a1b1 = .3571, 95% CI [.0948, .7162]) and lower levels of CVD risk through perceived control (a2b2 = -.1855, 95% CI [-.4388, -.0077]). Black prisoners had higher levels of CVD risk through health literacy influenced by perceived control (a1b2d21 = .0627, 95% CI [.0028, .1409]) indicating that despite the protective effect of higher levels of perceived control in black prisoners, CVD risk remained higher compared to their white counterparts. Conclusion Future CVD risk reduction interventions in prisoners of all races, but specifically black male prisoners, should include goals of improving health literacy and perceived control in addition to the traditional modifiable risk factors often included in biobehavioral interventions.


Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Lorraine M Novosel ◽  
Salina A Smialek

Depression is a risk factor for as well as a comorbidity of cardiovascular disease (CVD) in older adults (OA). Providers must target efforts toward the prevention, recognition, diagnosis, and treatment of depression to reduce CVD burden and morbidity and mortality among our rapidly growing aging population. While the AHA recommends routine screening for depression in all individuals with heart disease and the scientific community considers elevating depression to the status of "formal" CVD risk factor, depression remains under-diagnosed and sub-optimally treated by cardiology and primary care physicians. Nurse practitioners (NPs), utilizing a biopsychosocial model of care have a significant role in screening, health promotion, and risk reduction efforts and are positioned to play a vital role in primary care. This mixed-method study explored NPs’ knowledge, screening and risk reduction behaviors related to depression-CVD in OA. We hypothesized that NPs integrate depression screening, diagnosis and treatment into CVD risk reduction and management. Methods. A national sample of NPs (N=118) completed an anonymous survey. A subset (n=12) participated in a follow-up interview. Results: The NPs were aware of the high prevalence of depression among OA with CVD and identified depression as a risk for CVD. One-half were unaware of the AHA recommendation for depression screening or Medicare depression screening and cardiovascular preventive services. Yet, 70% routinely screened their OA patients, and OA patients with CVD for depression. The NPs (92.7%) were confident in their ability to address classic CVD risks and stressed the importance of a quality patient relationship to optimize depression care. A majority (64%) felt it would be at least “somewhat” easy to incorporate depression into their routine CVD risk reduction practices if depression became a “formal” CVD risk factor. Inadequate counseling skills and lack of mental health resources were cited as challenges. Conclusions. NPs are confident in their ability to promote CVD risk reduction among their OA patients and recognize and address depression in cardiovascular care. They are prepared to incorporate depression into CVD risk reduction practice but lack depression counseling resources.


2005 ◽  
Vol 38 (16) ◽  
pp. 38
Author(s):  
MICHELE G. SULLIVAN

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 664-P
Author(s):  
JODI KRALL ◽  
KRISTINE RUPPERT ◽  
ANA M. DIAZ ◽  
JESSICA FINNEY ◽  
LINDA M. SIMINERIO ◽  
...  

2021 ◽  
Vol 8 (2) ◽  
Author(s):  
Mabel Toribio ◽  
Evelynne S Fulda ◽  
Sarah M Chu ◽  
Zsofia D Drobni ◽  
Magid Awadalla ◽  
...  

Abstract Women with HIV (WWH) transitioning through menopause have heightened cardiovascular disease (CVD) risk. In the general population, hot flash burden relates to CVD risk indices. We found higher hot flash burden among women with vs without HIV. Further, among WWH, hot flash burden related to select CVD risk indices. ClinicalTrials.gov Registration NCT02874703.


2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
J Westerink ◽  
K Sommer Matthiessen ◽  
S Nuhoho ◽  
U Fainberg ◽  
M Lyng Wolden ◽  
...  

Abstract Introduction Cardiovascular disease (CVD) is the leading cause of disability and death in people with type 2 diabetes (T2D). In a post hoc analysis of pooled data (POOLED cohort) from two phase 3, randomized CV outcomes trials, SUSTAIN 6 (NCT01720446) and PIONEER 6 (NCT02692716), the addition of the glucagon-like peptide-1 analogue semaglutide to standard of care (SoC) in people with T2D at high risk of CVD significantly reduced the risk of major adverse CVD events (3-point MACE: CV death, non-fatal stroke and non-fatal myocardial infarction). Purpose To estimate the effect of adding semaglutide to SoC on CVD-free life-years and 10-year CVD risk in patients with T2D by predicting individual patient-level risk of CVD events in the POOLED cohort using the DIAL CVD risk model. Methods The 3-point MACE hazard ratio from the POOLED cohort (N=6480; HR = 0.76 [95% confidence interval [CI]: 0.62–0.92]) was applied to the patient-level lifetime risk of CVD events derived from the DIAL model. CVD-free life-years and 10-year CVD risk were then calculated based on the age-specific risks of CVD events and non-vascular mortality, using standard actuarial methods. Both new and recurrent CVD events were considered. The DIAL model was validated by comparing the predicted and observed number of CVD events after 1 year. The DIAL model was previously developed using data from people with T2D in the Swedish National Diabetes Registry and validated across geographical regions. Results The DIAL model was considered valid for use in the POOLED cohort because the predicted number of CVD events at 1 year was within 5% of the number observed. Adding semaglutide to SoC was associated with a mean reduction in 10-year CVD risk of 20.0% (95% CI: 6.4–32.6%) and a mean increase of 1.72 (95% CI: 0.52–2.96) CVD-free life-years. The number of mean CVD-free life-years gained ranged from 0.62–2.91 years between age groups (Table). For a 60-year-old male with baseline characteristics matched to the average male from the POOLED cohort, adding semaglutide to SoC reduced 10-year CVD risk by 20.8% and provided 2.53 additional CVD-free life-years. The number of CVD-free life-years decreased when baseline age was increased (Figure). Conclusions The addition of semaglutide to SoC was associated with a gain in CVD-free life-years. This analysis helps contextualize the results of CV outcomes trials and may help to inform clinical decision-making. Funding Acknowledgement Type of funding source: Private company. Main funding source(s): Novo Nordisk A/S


Sign in / Sign up

Export Citation Format

Share Document